Abliva Ab Aktie - 0QDU

Professionelle Tools für Privatanleger.

Premium

Current Price

2,65

Gebot

0,00

Fragen

0,00

Volumen

0,00

0,00 Tagesbereich 0,00

2,65 52-Wochen-Bereich 2,65

Marktkapitalisierung

2,799B

Handelsende

2,65

Handelsbeginn

Letzte Trade

(O)

Letzter Handelszeitpunkt

Finanzvolumen

VWAP

Durchschnittliches Volumen (3 Mio.)

12.697

Ausgegebene Aktien

1.056.299.000

Dividendenrendite

Kurs-Gewinn-Verhältnis

-0,33

Gewinn pro Aktie (EPS)

-0,09

Erlöse

137k

Nettogewinn

-95,51M

Sektor

Med, Dental, Hosp Eq-whsl

Branche

Med, Dental, Hosp Eq-whsl

Website

www.abliva.com

Hauptsitz

Lund, Swe

Gegründet

Abliva Ab is listed in the Med, Dental, Hosp Eq-whsl sector of the Londoner Börse with ticker 0QDU. The last closing price for Abliva Ab was SEK2,65. Over the last year, Abliva Ab shares have traded in a share price range of SEK 2,65 to SEK 2,65.

Abliva Ab currently has 1.056.299.000 shares in issue. The market capitalisation of Abliva Ab is SEK2,80 billion. Abliva Ab has a price to earnings ratio (PE ratio) of -0.33.

NeuroVive Pharmaceutical AB Year End Report January - December 2019

NeuroVive Pharmaceutical AB Year End Report January - December 2019 PR Newswire STOCKHOLM, Feb. 19, 2020 STOCKHOLM, Feb. 19, 2020 /PRNewswire/...

NeuroVive Pharmaceutical AB Year End Report January - December 2019

NeuroVive Pharmaceutical AB Year End Report January - December 2019 PR Newswire STOCKHOLM, Feb. 19, 2020 STOCKHOLM, Feb. 19, 2020 /PRNewswire/...

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study PR Newswire LUND, Sweden, Dec. 20, 2019 LUND...

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study PR Newswire LUND, Sweden, Dec. 20, 2019 LUND...

NeuroVive Announces Settlement in Dispute With CicloMulsion AG

NeuroVive Announces Settlement in Dispute With CicloMulsion AG PR Newswire LUND, Sweden, Dec. 16, 2019 LUND, Sweden, Dec. 16, 2019 /PRNewswire/...

NeuroVive Announces Settlement in Dispute With CicloMulsion AG

NeuroVive Announces Settlement in Dispute With CicloMulsion AG PR Newswire LUND, Sweden, Dec. 16, 2019 LUND, Sweden, Dec. 16, 2019 /PRNewswire/...

NeuroVive Pharmaceutical AB Interim Report January - September 2019

NeuroVive Pharmaceutical AB Interim Report January - September 2019 PR Newswire STOCKHOLM, Nov. 20, 2019 - Continued Progress in KL1333...

NeuroVive Pharmaceutical AB Interim Report January - September 2019

NeuroVive Pharmaceutical AB Interim Report January - September 2019 Continued Progress in KL1333 PR Newswire STOCKHOLM, Nov. 20, 2019 STOCKHOLM...

NeuroVive Pharmaceutical AB Interim Report January - June 2019

NeuroVive Pharmaceutical AB Interim Report January - June 2019 PR Newswire STOCKHOLM, Aug. 21, 2019 Focus on genetic mitochondrial diseases...

NeuroVive Pharmaceutical AB Interim Report January - June 2019

NeuroVive Pharmaceutical AB Interim Report January - June 2019 Focus on genetic mitochondrial diseases PR Newswire STOCKHOLM, Aug. 21, 2019...

Zeitraum †	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	2.65	2.65	2.65	0	0	DE
4	2.65	2.65	2.65	0	0	DE
12	2.65	2.65	2.65	12697	2.65	DE
26	2.65	2.65	2.65	8274	2.65	DE
52	2.65	2.65	2.65	4229	2.65	DE
156	2.65	2.65	2.65	2562	2.65	DE
260	2.65	2.65	2.65	2122	2.65	DE

0QDU - Frequently Asked Questions (FAQ)

What is the current Abliva Ab share price?

The current share price of Abliva Ab is SEK 2,65

How many Abliva Ab shares are in issue?

Abliva Ab has 1.056.299.000 shares in issue

What is the market cap of Abliva Ab?

The market capitalisation of Abliva Ab is SEK 2,8B

What is the 1 year trading range for Abliva Ab share price?

Abliva Ab has traded in the range of SEK 2,65 to SEK 2,65 during the past year

What is the PE ratio of Abliva Ab?

The price to earnings ratio of Abliva Ab is -0,33

What is the cash to sales ratio of Abliva Ab?

The cash to sales ratio of Abliva Ab is 300

What is the reporting currency for Abliva Ab?

Abliva Ab reports financial results in SEK

What is the latest annual turnover for Abliva Ab?

The latest annual turnover of Abliva Ab is SEK 137k

What is the latest annual profit for Abliva Ab?

The latest annual profit of Abliva Ab is SEK -95,51M

What is the registered address of Abliva Ab?

The registered address for Abliva Ab is MEDICON VILLAGE, SCHEELEVAGEN 2, LUND, 223 81

What is the Abliva Ab website address?

The website address for Abliva Ab is www.abliva.com

Which industry sector does Abliva Ab operate in?

Abliva Ab operates in the MED, DENTAL, HOSP EQ-WHSL sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
PREPensana Plc	35,40p (26,88%)	5,24M
CHARChariot Limited	1,70p (21,43%)	14,83M
GLRGalileo Resources Plc	0,95p (18,75%)	11,36M
UOGUnited Oil & Gas Plc	0,08p (18,52%)	183,38M
MILAMila Resources Plc	0,225p (18,42%)	14,09M
GEOGeo Exploration Limited	0,1125p (-91,96%)	40,32M
ENETEthernity Networks Ltd	0,0275p (-35,29%)	348,14M
IQAIIq-ai Limited	0,975p (-30,36%)	3,88M
ADMEAdm Energy Plc	0,175p (-30,00%)	44,81M
BIGBig Technologies Plc	75,00p (-28,57%)	8,68M
PREMPremier African Minerals Limited	0,0109p (-6,44%)	1,03B
CPXCap-xx Limited	0,13p (4,00%)	390,96M
LLOYLloyds Banking Group Plc	70,24p (0,60%)	355,05M
TRPTower Resources Plc	0,023p (6,98%)	354M
ENETEthernity Networks Ltd	0,0275p (-35,29%)	348,14M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Abliva Ab (0QDU)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Abliva Ab

0QDU Neueste Nachrichten

NeuroVive Pharmaceutical AB Year End Report January - December 2019

NeuroVive Pharmaceutical AB Year End Report January - December 2019

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study

NeuroVive Announces Settlement in Dispute With CicloMulsion AG

NeuroVive Announces Settlement in Dispute With CicloMulsion AG

NeuroVive Pharmaceutical AB Interim Report January - September 2019

NeuroVive Pharmaceutical AB Interim Report January - September 2019

NeuroVive Pharmaceutical AB Interim Report January - June 2019

NeuroVive Pharmaceutical AB Interim Report January - June 2019

0QDU - Frequently Asked Questions (FAQ)

Beweger

0QDU Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Abliva Ab (0QDU) Börsenkurse

Abliva Ab (0QDU)

Professionelle Tools für Privatanleger.

Wichtige Statistiken und Details

Über Abliva Ab

0QDU Neueste Nachrichten

NeuroVive Pharmaceutical AB Year End Report January - December 2019

NeuroVive Pharmaceutical AB Year End Report January - December 2019

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study

NeuroVive Announces Settlement in Dispute With CicloMulsion AG

NeuroVive Announces Settlement in Dispute With CicloMulsion AG

NeuroVive Pharmaceutical AB Interim Report January - September 2019

NeuroVive Pharmaceutical AB Interim Report January - September 2019

NeuroVive Pharmaceutical AB Interim Report January - June 2019

NeuroVive Pharmaceutical AB Interim Report January - June 2019

0QDU - Frequently Asked Questions (FAQ)

Beweger

0QDU Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen